About Recombinant Protein Expression and the UNLOCK PICHIA® Platform
When you work with VALIDOGEN, you work with a team of experts with more than 15 years of experience in Pichia pastoris strain and process development. Our focus is delivering robust, high-performing strains and processes that accelerate your protein development success.
Unlike standard providers, everything we do is tailored to your project’s specific needs. By combining our UNLOCK PICHIA® platform with deep scientific expertise, we deliver customized solutions rather than one-size-fits-all services — ensuring the best chance of success for your protein. Our exclusive focus on Pichia pastoris further sets us apart, enabling us to apply unmatched depth of knowledge and optimization to every project.
Our services are valuable for a wide range of organizations:
Projects typically begin with a discussion of your protein(s) and goals, followed by a tailored proposal outlining possible strategies, timelines, and deliverables. We aim to make the onboarding process clear, collaborative, and efficient.
We optimize strains and processes for scalability, robustness, and reproducibility. A quick, low-cost feasibility study can also confirm early whether your protein will express successfully, helping to reduce risk before full-scale development.
Simply reach out to us via our contact page. We’ll set up an initial conversation to understand your needs and explore how we can help.
VALIDOGEN combines advanced Pichia strain development with fermentation and purification process development to improve productivity, process robustness, scalability, and overall process economics. Depending on the target protein, application, and production requirements, projects can be designed using methanol-induced or methanol-free expression strategies, including ARMs-free strain options. This enables flexible solutions for biopharma, food and feed, industrial biotechnology, and diagnostics applications.
Feasibility studies provide a fast and cost-efficient way to check how well your protein can be expressed in Pichia pastoris. They allow you to obtain an early indication of success and a small sample for testing before committing to a larger development project. This reduces risk and supports informed decision-making at an early stage.
We create non-optimized stable strains using a few molecular tools from our UNLOCK PICHIA toolbox, test expression at microscale, and if needed, scale up to a 1 L bioreactor for a small protein sample, which can be purified if desired.
Feasibility studies are designed to be fast-track projects. Strain development can take as little as 4 weeks, followed by 2–5 weeks for cultivation and purification, depending on requirements.
We leverage our expertise and our proprietary UNLOCK PICHIA® toolbox of promoters, secretion signals, co-expression helper factors, and platform strains. By generating extensive genetic diversity and systematically screening for high-performing strains, we can identify optimal expression solutions for each individual protein.
Methanol-free Pichia pastoris strains are specifically engineered to achieve high-level protein expression without the need for methanol induction. The benefits include:
The choice depends on your protein, its intended application, or production site. For food, feed, or similar applications, methanol-free strains may be required.
In other cases, we recommend evaluating both methanol-induced and methanol-free systems, since performance can vary depending on the specific protein. Our team can design comparative development strategies to identify the best-performing option for your project.
Timelines vary depending on project scope and complexity:
VALIDOGEN combines proprietary secretion signals with helper-factor co-expression to improve recombinant protein secretion in Pichia pastoris. Our secretion signals can outperform the conventional α-MF signal, while selected helper factors support protein folding and processing. This enables target-specific optimization of secretion efficiency and productivity.
VALIDOGEN applies a systematic screening approach as part of its Expression Feasibility Studies. Multiple secretion signals are evaluated in parallel together with other critical expression parameters, enabling data-driven selection of the most effective secretion strategy for each target protein.
Yes. VALIDOGEN develops recombinant Pichia pastoris production strains using antibiotic-free selection strategies, including auxotrophic selection systems. ARMs-free strain development is particularly advantageous for applications in food, feed, industrial biotechnology and other sectors, where regulatory requirements, product safety considerations and consumer acceptance may favor production strains without antibiotic resistance markers.
Yes. Codon optimization is generally performed at the beginning of the project and serves as the basis for synthetic gene synthesis and subsequent expression studies.
Deletion of the AOX1 gene results in Pichia pastoris strains with a MutS (methanol utilization slow) phenotype. Since these strains rely on AOX2 only for the first step of methanol metabolism, they exhibit reduced methanol utilization compared to Mut+ strains. In methanol-induced fermentation, this reduces oxygen demand and heat generation while enabling more controlled methanol consumption and induction. VALIDOGEN’s UNLOCK PICHIA® platform strains are based on the MutS phenotype, providing a robust basis for efficient methanol-induced recombinant protein production. VALIDOGEN’s methanol-free UNLOCK PICHIA® technology however takes this one giant step further, and eliminates methanol entirely, simplifying process handling and supporting safer large-scale manufacturing.
Yes. Multi-copy integration can be applied during Pichia pastoris strain development to generate strains containing multiple copies of the gene of interest. However, high gene copy numbers are not always required to achieve strong expression. VALIDOGEN’s exclusive promoter toolbox can deliver high transcriptional activity without the need to substantially increase copy number. Therefore, VALIDOGEN typically develops low- to medium-copy strains, which can help maintain genetic stability while still achieving high recombinant protein productivity.
No. A higher gene copy number does not necessarily result in higher recombinant protein productivity. While multi-copy strains can increase transcription of the target gene, very high transcript levels may overload cellular processes involved in translation, protein folding, and protein secretion. This can lead to reduced growth, intracellular accumulation, product degradation or decreased secretion efficiency.
For this reason, VALIDOGEN uses screening and experimental characterization to identify the optimal balance between gene copy number, expression strength and cellular production capacity. The objective is not simply to maximize the number of gene copies integrated, but to develop a robust production strain with high product yield and quality.
Early development enables you to optimize strain performance and fermentation conditions before moving into scale-up or expensive GMP environments. At VALIDOGEN, this work is supported by the proprietary UNLOCK PICHIA® technology platform as a proven basis for robust and scalable Pichia process development. This approach reduces tech transfer risk and ensures a smoother, more cost-efficient transition into manufacturing.
Yes. Even if the strain was developed elsewhere, we can apply our expertise in Pichia fermentation to optimize expression levels, productivity, and process robustness. This often results in significantly higher yields and lower costs compared to unoptimized processes.
Yes. Our development is always performed with scalability in mind. Processes optimized in our labs are designed to transfer smoothly to industrial fermentation facilities, maintaining productivity and product quality at large scale. VALIDOGEN-developed processes have been successfully scaled to GMP processes of up to 100,000 L and to industrial enzyme production of up to 200,000 L.
We develop processes at scales up to 10 L bioreactors. VALIDOGEN is not a GMP facility - instead, we deliver tech-transfer-ready processes that can be handed over to your selected CDMO for GMP manufacturing. We have undertaken many such transfers.
A tech-transfer-ready process is one that has been well characterized and optimized, with robust fermentation conditions, reproducible performance, and thorough documentation. This ensures that a CDMO can implement the process at larger scale without additional major development steps.
Yes. VALIDOGEN is best known for its expertise in Pichia pastoris protein expression using the proprietary UNLOCK PICHIA® platform, which remains our core technology for recombinant protein production.
Building on more than 15 years of microbial bioprocess development experience, we also support clients with protein production, fermentation optimization and downstream purification for other microbial hosts, including E. coli. This complementary capability enables us to support a broader range of microbial protein production processes while maintaining our strong specialization in Pichia-based expression systems.
VALIDOGEN has developed Pichia pastoris (Komagataella phaffii) fermentation processes for a wide range of recombinant proteins, including antibody fragments such as vHHs/nanobodies, vaccine antigens, peptide hormones, growth factors and cytokines, serum proteins, therapeutic and industrial enzymes, as well as food and feed proteins. This broad experience enables tailored processes for high titers, product quality, robustness, and scalable manufacturing.
Yes. Methanol-free expression has been an established capability at VALIDOGEN for more than 15 years and has been commercially implemented in bioreactors of up to 200,000 L. VALIDOGEN's third-generation methanol-free promoters have substantially increased productivity: using generic, non-optimized 1 L bioreactor protocols, supernatant titers exceeding 20 g/L have been achieved across several protein classes. These results show that methanol-free expression can match, and in selected cases exceed, the performance of classical methanol-induced systems, while avoiding the operational, safety, and regulatory considerations linked to methanol induction. These titers can then be further increased through dedicated process development.
VALIDOGEN has achieved up to 5-fold titer improvements beyond already high-performing platform processes, maximizing productivity while reducing manufacturing costs. Substantially. VALIDOGEN's case studies show how systematic process development moves a Pichia process from a functional baseline to manufacturing-ready performance. In one methanol-induced bivalent VHH project an increase from 21 g/L to 31 g/L titer was reached just through process development. Two further case studies document methanol-free production optimized for maximum product titer and space-time yield (STY).
We apply a broad range of chromatographic and non-chromatographic purification methods depending on the target protein and its application. Chromatographic techniques typically include ion exchange, hydrophobic interaction, mixed mode, and affinity chromatography, often combined in multi-step strategies to achieve the desired purity and yield.
In addition to chromatography, we can apply diafiltration, ultrafiltration, precipitation, and extraction methods as part of the purification workflow. These approaches can simplify the process, reduce costs, or serve as preparatory steps before final chromatographic purification.
Purity levels depend on the protein and intended use. In most cases, our workflows achieve high-purity protein suitable for research and preclinical applications. For industrial enzymes, purification can be tailored to cost-effectiveness rather than maximum purity, while for therapeutic candidates, very high purity levels can be reached through optimized multi-step processes.
Yes. Building on more than 15 years of microbial bioprocess development experience, we also support clients with downstream purification for other microbial hosts, including other yeasts and E. coli.
UNLOCK PICHIA® is VALIDOGEN’s proprietary platform, developed from decades of expertise in Pichia. It stands out because it combines a broad toolbox of genetic elements (promoters, secretion signals, co-expression factors, platform strains) with high-throughput screening and systematic optimization strategies. This enables rapid identification of top-performing strains tailored to each protein’s requirements.
Yes. UNLOCK PICHIA® includes methanol-free expression systems, eliminating the need for methanol induction. This makes it suitable for sensitive industries such as food & feed, and agriculture, or working at large scale, while maintaining high expression levels.
It stands out because it combines a broad toolbox of genetic elements (promoters, secretion signals, co-expression factors, platform strains) with high-throughput screening and systematic optimization strategies. This enables rapid identification of top-performing strains tailored to each protein’s requirements.
Yes. Through glyco-engineered strains, we can modify the glycosylation pattern of proteins expressed in Pichia pastoris, allowing production of proteins with human-like N-glycosylation, where potential immunogenicity of the product is a concern.
Optimization is achieved by systematically combining different promoters, secretion signals, helper factors, and strain backgrounds to generate genetic diversity. High-throughput screening then identifies strains with superior expression, secretion, and product quality, leading to significantly higher protein yields.
Genetic modifications are typically introduced via molecular cloning and targeted integration of expression cassettes designed to work efficiently in Pichia.
Pichia pastoris is a proven production host that delivers high yields at low cost. It grows on simple media, reaches very high biomass, and can be scaled easily from lab to industrial fermenters. With secretion capability and eukaryotic folding machinery, it bridges the gap between bacterial and mammalian systems.
Compared to mammalian cell lines, Pichia offers:
Unlike E. coli, Pichia is a eukaryote and can:
No. While traditional Pichia expression systems use methanol-inducible promoters, methanol-free systems are also available. These eliminate the need for methanol handling and are especially useful in regulated industries such as food & feed, and agriculture, or when working at large scale.
Yes. Pichia has been used to manufacture of approved biopharmaceutical products and is recognized as a reliable and scalable production host. The clinical pipeline shows that it is an attractive host for diverse protein formats such as domain antibodies. It is particularly attractive for biologics requiring high yields and cost-effective production.
Yes. Pichia pastoris has obtained GRAS (Generally Recognized as Safe) status for many applications, and is on the EFSA QPS (Qualified Presumption of Safety) list. It is widely considered a safe microbial host for production in the food and feed industries. For some feed applications the supernatant is pure enough that it can be used directly with no downstream processing.
Pichia is used across industries to produce a wide range of recombinant proteins and peptides, including antibody fragments (e.g. VHHs/nanobodies), growth factors, peptide hormones, cytokines, vaccine antigens, serum proteins, and both therapeutic and industrial enzymes. This versatility makes it a go-to system for applications in healthcare, biotechnology, food, feed, and industrial bioprocesses.
Yes. Whether you already have a Pichia production strain or need VALIDOGEN to develop one, we design and optimize scalable fermentation processes for recombinant biopharmaceuticals, ready for technology transfer, scale-up and GMP manufacturing at your selected CMO or CDMO.
Pichia pastoris is a commercially validated platform that combines microbial productivity with eukaryotic folding and secretion. It is suited for a wide range of protein classes including cytokines, growth factors, enzymes, recombinant antigens and VLPs, antibody fragments such as Fab, scFv and VHH formats, and selected serum and fusion proteins.
It is not a universal replacement for CHO or E. coli, but a strong alternative when product quality, scalability and production economics fit the molecule. Target-specific strain development and tailored process development can enable the production of challenging or difficult-to-express proteins.
Yes. Pichia pastoris is an established host for antibody fragments such as VHHs/sdAbs, and VALIDOGEN develops high-performance production strains and scalable processes for these formats. See our VHH production case study for a documented example of UNLOCK PICHIA® strain and process optimization.
Yes. VALIDOGEN has more than 15 years of experience with methanol-free Pichia expression and develops high-performance strains and scalable processes without methanol induction. Performance is comparable to - and in some cases exceeds - methanol-induced systems, while simplifying process handling and facility requirements and supporting robust scale-up and GMP manufacturing.
For biopharmaceutical programs, the optimal strategy depends not only on expression performance but also on product quality, process robustness, scale-up requirements and compatibility with the intended GMP manufacturing site. VALIDOGEN can evaluate methanol-induced and methanol-free systems in parallel to identify the option that best balances productivity, product quality and manufacturability for your clinical development and CMC strategy.
Yes. VALIDOGEN can supply non-GMP protein for analytical, formulation and preclinical studies. We also deliver technology-transfer-ready processes for implementation by your selected CDMO/CMO and have successfully supported numerous transfers into GMP manufacturing.
Yes. Whether you already have a Pichia production strain or need VALIDOGEN to develop one, we design and optimize scalable fermentation processes for food and feed proteins or enzymes - ready for tech transfer and large-scale manufacturing.
Yes. Pichia pastoris is well suited for food and feed applications due to its recognized safety profile, including GRAS and QPS relevance. As a microbial eukaryotic host, it supports protein folding, disulfide bond formation, and functional protein processing, while being naturally free from bacterial endotoxins and mammalian viral contaminants.
Yes. VALIDOGEN can provide protein material for testing, characterization, and evaluation from 1 L and 10 L bioreactor runs. When larger-scale manufacturing is required, the transfer-ready process developed by VALIDOGEN can be implemented by a CMO or manufacturing partner.
VALIDOGEN’s strain engineering and fermentation development work together to increase expression levels and establish an economically viable protein production process, helping reduce cost of goods during manufacturing. In addition, optimizing strain and process from the earliest project stages helps define the right production concept before scale-up, reducing technical risk and improving batch-to-batch consistency for high-volume food and feed markets.
VALIDOGEN's expression-enhancing tools, methanol-free and ARMs-free technology, and robust processes support consistent product quality, simplified scale-up, and lower cost of goods.
VALIDOGEN's E. coli fermentation process development services are designed for clients with established E. coli expression systems seeking expert support in process optimization, scale-up, and technology transfer. Expression strain generation can be performed upon request using commercially available E. coli strains selected by the customer. This enables VALIDOGEN to support projects where an E. coli expression construct is already available and the next step is to establish a suitable production strain for subsequent fermentation and purification process development.
For projects requiring strain engineering or alternative expression hosts, our proprietary UNLOCK PICHIA® platform enables the development of high-performance Pichia pastoris production strains with exceptional productivity.
Project timelines depend on the scope and complexity of the development program required. Our suite of parallel bioreactor systems enables rapid testing of multiple conditions, allowing efficient optimization and accelerated process development.
VALIDOGEN develops fermentation and purification processes at scales up to 10 L. While VALIDOGEN is not a GMP manufacturing facility, we deliver robust processes that can be efficiently implemented under GMP conditions at your selected CDMO or manufacturing partner.
Yes. In addition to fermentation process development, VALIDOGEN offers non-GMP protein production using your existing E. coli expression strain. We enable the rapid generation of protein samples in 1 L and 10 L bioreactor systems, providing sufficient material for early-stage evaluation, analytical testing, and functional studies. If required, proteins can be purified using established standard purification techniques.
With more than 15 years of experience in microbial protein production, VALIDOGEN provides process development expertise for a wide range of proteins across different industries including growth factors, enzymes and antibody fragments.
VALIDOGEN's core expertise is in strain and process optimization for recombinant protein expression in Pichia pastoris, supported by more than 15 years of experience in strain engineering, fermentation process development, and scale-up. Leveraging extensive microbial process know-how and a long-standing technology and R&D collaboration with Boehringer Ingelheim, VALIDOGEN also offers E. coli fermentation process development and non-GMP protein production. These services support customers with existing E. coli expression strains who require protein samples, process optimization, scale-up, or technology transfer support.
